Sclerosing treatment of lymphangiomas with OK-432.

Abstract

Over a period of seven years, 15 patients (aged from birth to 15 years; median 22 months) with lymphangioma were treated with OK-432; they received a mean of three injections each. Ten received OK-432 as first line treatment; five were treated after surgery (three had a residual lymphangioma after incomplete removal and two had a late recurrence). OK-432 proved to be effective for primitive as well as for residual and recurrent lymphangioma. Seven cases were macrocystic; complete regression was obtained in all. Five cases were microcystic: two had more than 50% regression, and three less than 50%. Three cases were mixed, with both large and microscopic cysts: one had more than 50% regression, and two less than 50%. These last two cases underwent surgery after the sclerosing treatment. The results obtained were excellent in 100% of macrocystic cases; a shrinkage in size was obtained in all microcystic cases. OK-432 is therefore proposed as a first line option for treatment of lymphangiomas.

• Authors: C Luzzatto, P Midrio, Z Tchaprassian, M Guglielmi
• Journal: Archives of disease in childhood (Arch Dis Child) Vol. 82 Issue 4 Pg. 316-8 (Apr 2000) ISSN: 1468-2044 [Electronic] England
• PMID: 10735841 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Picibanil

Topics

• Adolescent
• Antineoplastic Agents (therapeutic use)
• Child
• Child, Preschool
• Head and Neck Neoplasms (therapy)
• Humans
• Infant
• Infant, Newborn
• Lymphangioma (diagnostic imaging, therapy)
• Picibanil (therapeutic use)
• Radiography
• Sclerotherapy (methods)